Arrivent BioPharma, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

282.58 k

Shareholding (Mar 2025)

FII

22.33%

Held by 40 FIIs

DII

34.02%

Held by 21 DIIs

Promoter

25.98%

How big is Arrivent BioPharma, Inc.?

22-Jun-2025

As of Jun 18, Arrivent BioPharma, Inc. has a market capitalization of 854.63 million and reported net sales of 0.00 million with a net profit of -127.45 million over the last four quarters. Shareholder's funds were valued at 257.65 million, and total assets amounted to 274.94 million.

What does Arrivent BioPharma, Inc. do?

22-Jun-2025

Arrivent BioPharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $64 million and a market cap of $854.63 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -39.74%.

Is Arrivent BioPharma, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Arrivent BioPharma, Inc. shows a mildly bearish technical trend with conflicting signals, underperforming the S&P 500 with a year-to-date return of -25.11% compared to the index's 14.18%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 820 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.94

Return on Equity

-54.82%

Price to Book

3.28

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-31 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

20.3%

6 Months

-11.18%

1 Year

-14.14%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Arrivent BioPharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Arrivent BioPharma, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Arrivent BioPharma, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the Bollinger Bands and moving averages show a mildly bearish trend. The KST is bearish on a weekly basis, and Dow Theory suggests a mildly bullish outlook on the weekly timeframe. Overall, the technical stance is mildly bearish with some conflicting signals. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -25.11% versus the S&P 500's 14.18%, and a one-year return of -26.82% compared to 17.82% for the benchmark....

Is Arrivent BioPharma, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Arrivent BioPharma, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe, mildly bearish Bollinger Bands, and mildly bearish moving averages on the daily timeframe. The KST and OBV indicators are also bearish on the weekly timeframe. In terms of performance, the stock has returned 10.04% over the past week, significantly outperforming the S&P 500's 1.09%, but it has underperformed over the longer terms, with a year-to-date return of -25.53% compared to the S&P 500's 14.18%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-26.44%

EBIT to Interest (avg)

-84.45

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.87

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

93.27%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.97

EV to EBIT

-6.67

EV to EBITDA

-6.67

EV to Capital Employed

23.63

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-354.50%

ROE (Latest)

-39.74%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 24 Schemes (17.67%)

Foreign Institutions

Held by 40 Foreign Institutions (22.33%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -43.38% vs -1.39% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.60",
          "val2": "-25.70",
          "chgp": "-30.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.40",
          "val2": "-21.90",
          "chgp": "-43.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.16% vs -87.80% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-94.30",
          "val2": "-74.60",
          "chgp": "-26.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-80.50",
          "val2": "-69.30",
          "chgp": "-16.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-33.60

-25.70

-30.74%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-31.40

-21.90

-43.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -43.38% vs -1.39% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-94.30

-74.60

-26.41%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-80.50

-69.30

-16.16%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -16.16% vs -87.80% in Dec 2023

All Annual Results

Company CV

About Arrivent BioPharma, Inc.

Arrivent BioPharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Arrivent BioPharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Arrivent BioPharma, Inc.?

Watch in Real-Time

What does Arrivent BioPharma, Inc. do?

Is Arrivent BioPharma, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Arrivent BioPharma, Inc. technically bullish or bearish?

Is Arrivent BioPharma, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Arrivent BioPharma, Inc.

Company Coordinates